Covid-19 has had a great impact on global clinical trials, and the RELEASE study is no exception. Slow patient recruitment will delay the interim read-out of RELEASE by 6-12 months. To counter the Covid-19 impact, PCIB will include more sites in Asia, which could also provide a market upside with a drug approval. With increased study costs, the company is most likely not fully funded all the way to the planned interim read-out in end 2022.
27 Aug 2020
Covid-19 impacts patient recruitment
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Covid-19 impacts patient recruitment
Covid-19 has had a great impact on global clinical trials, and the RELEASE study is no exception. Slow patient recruitment will delay the interim read-out of RELEASE by 6-12 months. To counter the Covid-19 impact, PCIB will include more sites in Asia, which could also provide a market upside with a drug approval. With increased study costs, the company is most likely not fully funded all the way to the planned interim read-out in end 2022.